Last updated: February 13, 2026
mmary
The drug identified by NDC 64764-0543 is Rexulti (brexpiprazole), developed and marketed by Otsuka Pharmaceutical Co., Ltd. and Lundbeck. Its primary indication is for schizophrenia and adjunctive treatment of major depressive disorder. Market analysis indicates a consistent growth trend driven by expanding indications, increasing prevalence of targeted disorders, and competitive dynamics. Price projections suggest a stable to slightly increasing cost trajectory through 2025, sustained by patent protections and limited generic competition.
Market Size and Adoption Trends
Rexulti launched in mid-2015; its market size expanded steadily, supported by favorable efficacy and safety profiles compared to competitors like Abilify and Latuda. Sales reached approximately $1.2 billion globally in 2022[1].
- Patient Population: Estimated 2.4 million U.S. patients with schizophrenia[2], with adjunctive MDD treatment applicable to roughly 13 million adults diagnosed annually[3].
- Market Penetration: Roughly 15% of eligible patients are treated with Rexulti in the U.S. and comparable markets, limiting yet steadily increasing market share.
- Competitive Landscape: Dominated by aripiprazole-based products; Rexulti's unique receptor-binding profile provides differentiation.
Regulatory and Patent Protection
The primary patent covering Rexulti expires in 2030, with regulatory exclusivities extending into 2032. No significant generic presence exists; bioequivalent competitors have not entered due to patent barriers[4].
Pricing Dynamics and Projections
- Current Pricing: The average wholesale price (AWP) for Rexulti is approximately $2,200 per month per patient[5]. Discounting and insurance negotiations reduce actual payer costs.
- Historical Trends: Over the past five years, Rexulti’s monthly treatment costs have increased at an annual rate of approximately 3%, influenced by inflation, new formulation introductions, and negotiated rebates.
- Projected Pricing: Through 2025, prices are expected to stabilize or increase modestly (2-3% annually) due to inflation, patent protections, and the lack of generics[6].
| Year |
Estimated Monthly Price |
Notes |
| 2023 |
$2,200 |
Current market price |
| 2024 |
$2,244 |
2% inflation adjustment |
| 2025 |
$2,291 |
2.2% compounded increase |
Revenue Projections
Considering market penetration, the global revenue forecast aligns proportionally with sales volume and price levels. With steady growth to 2025, global sales could reach approximately $1.5 billion, assuming a stabilization in market penetration and price[7].
Market Challenges and Opportunities
- Patent Expiry and Generics: Patent expiry in 2030 will likely induce price erosion. Early generic entrants could decrease prices by up to 50%, demanding strategic planning for when this occurs.
- Expansion into New Indications: Ongoing research into neurodegenerative and other psychiatric conditions may diversify revenue streams.
- Pricing and Reimbursement Pressures: Payers aim to contain costs, applying rebates or negotiating discounts, which could impact net revenue.
Key Takeaways
- Rexulti’s market growth is robust but plateauing as market saturation nears.
- Price stability is anticipated until patent expiry, with limited short-term risks of significant price erosion.
- Strategic pipeline developments and indication expansion could mitigate patent expiration impacts.
FAQs
- How does Rexulti’s price compare with similar antipsychotics?
- What factors could accelerate generic entry post-2030?
- How might negotiations with payers influence net price?
- What are the main risks affecting Rexulti’s market share?
- Are there significant regional variations in Rexulti’s pricing?
References
[1] IQVIA, 2022 sales data.
[2] CDC, Schizophrenia prevalence estimates, 2021.
[3] Substance Abuse and Mental Health Services Administration, Treatment Episode Data Set, 2021.
[4] U.S. Patent and Trademark Office, Patent expiration dates, 2022.
[5] Red Book Online, 2023.
[6] Market research reports, 2022.
[7] Analyst projections based on current market share and pricing trends.
